@bm)-; YA * @~~N#~[ ,]3,fL[6Y,- zRo}y \ n99ta 0hQ`!T:Nu d^_%@i%|K_K@ 7dJr T3#jxTzT3 |w xQGu|GGE (PGJ t9[UI^9s1t9atU\#At| |[j[a a8~*W~a QW@9`7KW9xK {?}d?06Eje0E{{ `HGsh7-Hw8- $ppXp`5= s711:k11D. \U! F,vFHav ao 0E/ l8H 6(Tvu KtKMLJjJ _5 Zo^? @B36g IUs *@~7~tp~v ig )+sB m:7G( ,6,.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Fe6qmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.